Clinical Trial Update: Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 safety and dosing study evaluated glucagon-like peptide 2 in infants and children with intestinal failure, including short bowel syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Failure
• Short Bowel Syndrome

Drugs mentioned

• Glucagon-like peptide-2 (glucagon-like peptide-2)

Snippet

Sponsor: Alberta Children's Hospital | Conditions: Intestinal Failure, Short Bowel Syndrome | Phase 1, Phase 2 | Status: TERMINATED